Skip to main content

Table 1 Recurrent thrombosis in the patients with antiphospholipid antibodies

From: Controversies in the antiphospholipid syndrome: can we ever stop warfarin?

Study design N Mean age
Years
Entry criteria Patient Characteristics Mean Follow up
Years
Patients with recurrent events
No. (%)
Number of recurrent events
All (arterial/venous)
Reference
Retrospective 70
48W
22M
45.5 ± 17.3 aPL (aCL/LA) + arterial/venous thrombosis (1st event) PAPS 51
SLE 14
ITP 5
5.2 37/70 (53%) 54 Rosove MH et al. Ann Intern Med 1992
Retrospective 19
16W
3M
26
(15–40)
aPL (aCL/LA) + venous thrombosis (1st event) PAPS 1
SLE 12
Lupus like 6
8 12/19 (63%) 37 (3/34) Derksen R et al. Ann Rheum Dis 1993
Retrospective 147
124W
23M
32
(14–66)
aPL (aCL/LA) + arterial/venous thrombosis (1st event) PAPS 62
SLE 66
Lupus like 19
7 101/147 (69%) 186 (75/111) Khamashta M et al. N Eng J Med 1995
Prospective 360
242W
118M
39
(2–78)
aPL (aCL/LA) (117 aPL pt with previous arterial/venous thrombosis) SLE 69
Lupus like 66
4 25/117 (21.3%) 25 Finazzi G et al. Am J Med 1996
Prospective 412
181W
231M
60.2 Venous thrombosis (1st event) allocated 6 months warfarin - 4 20/68 aCL+ (29%)
47/344 aCL- (14%)
67 (-/67) Schulman S et al. Am J Med 1998
Prospective 56
48W
8M
37 ± 10 APS (aPL + thrombosis and/or fetal loss)
(43 patients with previous arterial/venous thrombosis)
PAPS only 5 14/43 (32.5) 16 (10/6) Turiel M et al. Stroke 2005
  1. W – women; M – men; aPL – antiphospholipid antibodies; aCL – anticardiolipin antibodies; LA – lupus anticoagulant; PAPS – primary antiphospholipid syndrome; SLE – systemic lupus erytematosus; Lupus like – Lupus like disease; ITP – chronic idiopathic thrombocytopenic purpura.